FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

Business

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.

Read the original report.

Articles You May Like

ASIC warns super funds: stop blaming members and fix your complaints handling
Workers are dobbing in more employers than ever, and the Fair Work Ombudsman is chasing $453m
Wyden Raises The Profile Of Long-Term Care Reform But Has Far To Go
What the Democratic midterms sweep changes for U.S.-China relations
Barkin sees interest rate hikes ahead, but at a gradual pace

Leave a Reply

Your email address will not be published. Required fields are marked *